No Data
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
SSY Group Expands Pharmaceutical Portfolio With New Approvals
SSY GROUP (02005.HK): Obtained the Pharmaceutical production registration approval for Dapagliflozin Metformin Extended-Release Tablets (Ⅰ) (Dapagliflozin 10mg and Metformin Hydrochloride 1000mg) and Arginine Ibuprofen Granules (0.4g and 0.2g).
On April 22, Gelonghui reported that SSY GROUP (02005.HK) has obtained the drug production registration approval from the National Medical Products Administration of China for Dapagliflozin Metformin Sustained Release Tablets (I) (Dapagliflozin 10mg and Metformin Hydrochloride 1000mg) and Arginine Ibuprofen Granules (0.4g and 0.2g), both classified as Chemical Drugs Class 4, considered to have passed consistency evaluation. Dapagliflozin Metformin Sustained Release Tablets (I) are mainly used to improve blood sugar control in adult patients with type 2 diabetes, while Arginine Ibuprofen Granules are mainly used for the following symptoms: toothache, dysmenorrhea, pain caused by injury.
Express News | SSY Group - Group's Acipimox and Diprophylline Obtained Approvals for Registration From Nmpa
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
Has the SSE Health Care theme Index risen again? This year, the public fund performance has shuffled, with the highest return of the health care theme Fund exceeding 44%, and Inflow of capital has accelerated.
As of April 16, two SSE Health Care theme Index Funds have entered the top 10 performances of actively managed equity funds this year; Since April, multiple Hwabao WP CSI Medical Service ETFs have seen significant net subscriptions, with the total amount of fund shares for these medical ETFs reaching a new high; Fund managers believe that the pharmaceutical sector is not just undervalued in parts, but is comprehensively undervalued, and the nature of Innovative Drugs has changed.
Earnings Are Growing at SSY Group (HKG:2005) but Shareholders Still Don't Like Its Prospects
